Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Gross Profit: 2013-2024

Historic Gross Profit for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $138.1 million.

  • CytomX Therapeutics' Gross Profit fell 82.16% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.6 million, marking a year-over-year decrease of 10.26%. This contributed to the annual value of $138.1 million for FY2024, which is 36.45% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Gross Profit of $138.1 million as of FY2024, which was up 36.45% from $101.2 million recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' Gross Profit ranged from a high of $138.1 million in FY2024 and a low of $37.3 million during FY2021.
  • For the 3-year period, CytomX Therapeutics' Gross Profit averaged around $97.5 million, with its median value being $101.2 million (2023).
  • In the last 5 years, CytomX Therapeutics' Gross Profit surged by 154.36% in 2020 and then plummeted by 45.47% in 2021.
  • Yearly analysis of 5 years shows CytomX Therapeutics' Gross Profit stood at $68.4 million in 2020, then crashed by 45.47% to $37.3 million in 2021, then soared by 42.48% to $53.2 million in 2022, then spiked by 90.38% to $101.2 million in 2023, then surged by 36.45% to $138.1 million in 2024.